Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
While antiretroviral drugs have shown great promise in reducing HIV replication and thus in reducing HIV/AIDS associated morbi-mortality and HIV transmission, the cost is substantial and side effects are a potentially limiting factor. Development of an effective safe-affordable vaccine is likely to be the best way to stop further virus spread. The study aims to determine safety and immunogenicity of the DNA-vaccine at a dose of 600µg and 1200µg delivered id in combination with MVA-CMDR boost im.
Epistemonikos ID: b00830bd706c319039f1900748fbf10cd06072c1
First added on: May 06, 2024